Complementary Peptide Therapies in the GLP-1 Era As GLP-1 therapies (both injectable and oral) become the pharmacological foundation of metabolic disease management, complementary peptide therapies address aspects of health that GLP-1 alone doesn't fully cover
Notably, compound 12, featuring an ethyl hydrazide zinc-binding group (ZBG), achieved 53% oral bioavailability a significant advance over traditional hydroxamic acid-based inhibitors
Cell 117(3):399412 Stitt TN, Drujan D, Clarke BA, Panaro F, Timofeyva Y, Kline WO, Gonzalez M, Yancopoulos GD, Glass DJ (2004) The IGF-1/PI3K/Akt pathway prevents expression of muscle atrophy-induced ubiquitin ligases by inhibiting FOXO transcription factors
The Bottom Line: Should You Use Peptides